Exhibit 1.1
3,000,000 Shares
1
Vital Images, Inc.
Common Stock
PURCHASE AGREEMENT
November 16, 2006
PIPER JAFFRAY & CO.
Wachovia Capital Markets, LLC
Jefferies & Company, Inc.
Thomas Weisel Partners, LLC
As Representatives of the several
Underwriters named in Schedule I hereto
c/o Piper Jaffray & Co.
U.S. Bancorp Center
800 Nicollet Mall
Minneapolis, Minnesota 55402
Ladies and Gentlemen:
Vital Images, Inc., a Minnesota
corporation (the “ Company ”), proposes to sell
to the several Underwriters named in Schedule I hereto (the “
Underwriters ”) an aggregate of 3,000,000 shares (the
“ Firm Shares ”) of Common Stock, $0.01 par
value per share (the “ Common Stock ”), of the
Company. The Company has also granted to the several
Underwriters an option to purchase up to 450,000 additional shares
of Common Stock on the terms and for the purposes set forth in
Section 3 hereof (the “ Option Shares
”). The Firm Shares and any Option Shares purchased
pursuant to this Purchase Agreement are herein collectively called
the “ Securities .”
The Company hereby confirms its
agreement with respect to the sale of the Securities to the several
Underwriters, for whom you are acting as representatives (the
“ Representatives ”).
1.
Registration Statement and Prospectus . The Company has
prepared and filed with the Securities and Exchange Commission (the
“ Commission ”) a registration statement on Form
S-3 (File No. 333-137237), including the related preliminary
prospectus or prospectus, under the Securities Act of 1933, as
amended (the “ Securities Act ”), for the
registration of the Securities and other securities of the Company,
and the offering thereof from time to time in accordance with Rule
415 of the rules and regulations of the Commission promulgated
under the Securities Act (the “ Rules and Regulations
”). The prospectus contained in such registration
statement at the time it became effective is referred to herein as
the “ Base Prospectus .” Such registration
statement, at any given time, including amendments thereto to such
time, the exhibits and any schedules thereto at such time, the
documents incorporated by reference therein pursuant to Item 12 of
Form S-3 under the Securities Act at such time and the documents
and information otherwise deemed to be a part thereof or included
therein by Rule 430B under the Rules and
1
Plus an option to purchase up to 450,000 additional shares to cover
over-allotments.
Regulations (the
“ Rule 430B Information ”) or otherwise pursuant
to the Rules and Regulations at such time, is herein called the
“ Registration Statement .” Any
registration statement filed pursuant to Rule 462(b) of the
Rules and Regulations is herein referred to as the
“Rule 462(b) Registration Statement,” and, after
such filing, the term “ Registration Statement ”
shall include the Rule 462(b) Registration Statement. The
Registration Statement at the time it originally became effective
is herein called the “ Original Registration Statement
.”
Each
preliminary prospectus supplement to the Base Prospectus, together
with the Base Prospectus, that describes the Securities and the
offering thereof, that omitted the Rule 430B Information and that
was used prior to the filing of the final prospectus supplement
referred to in the following sentence is herein called a “
Preliminary Prospectus .” Promptly after
execution and delivery of this Agreement, the Company will prepare
and file with the Commission a final prospectus supplement to the
Base Prospectus relating to the Securities and the offering
thereof, together with the Base Prospectus, in accordance with the
provisions of Rule 430B and Rule 424(b) of the Rules and
Regulations (“ Rule 424(b) ”). Such
final prospectus supplement, together with the Base Prospectus, in
the form first furnished to the Underwriters to confirm sales of
the Securities at the time of the execution of this Agreement, is
herein called the “ Prospectus .” Any
reference herein to the Base Prospectus, any Preliminary Prospectus
or the Prospectus shall be deemed to refer to include the documents
incorporated by reference therein pursuant to Item 12 of Form S-3
under the Securities Act or the Securities Exchange Act of 1934, as
amended (the “ Exchange Act ”), as of the date
of such prospectus.
For purposes
of this Agreement, all references to the Registration Statement,
the Base Prospectus, any Preliminary Prospectus, the Prospectus or
any amendment or supplement to any of the foregoing shall be deemed
to include the copy filed with the Commission pursuant to its
Electronic Data Gathering, Analysis and Retrieval System (
“EDGAR” ). All references in this
Agreement to financial statements and schedules and other
information which is “described,”
“contained,” “included” or
“stated” in the Registration Statement, the Base
Prospectus, any Preliminary Prospectus or the Prospectus (or other
references of like import) shall be deemed to mean and include all
such financial statements and schedules and other information which
is incorporated by reference in or otherwise deemed by the Rules
and Regulations to be a part of or included in the Registration
Statement, the Base Prospectus, any Preliminary Prospectus or the
Prospectus, as the case may be; and all references in this
Agreement to amendments or supplements to the Registration
Statement, the Base Prospectus, any Preliminary Prospectus or the
Prospectus shall be deemed to mean and include the filing of any
document under the Exchange Act which is incorporated by reference
in or otherwise deemed by the Rules and Regulations to be a part of
or included in the Registration Statement, the Base Prospectus, any
Preliminary Prospectus or the Prospectus, as the case may
be.
2.
Representations and Warranties of
the Company.
(a)
The Company represents and warrants to, and agrees with, the
several Underwriters as follows:
(i)
No order preventing or suspending the use of any Preliminary
Prospectus has been issued by the Commission, and each Preliminary
Prospectus, at the Applicable Time (as hereinafter defined), the
time of filing, when any document filed under the Exchange Act that
is incorporated by reference into a Preliminary Prospectus was or
is filed, or
2
the time of first
use within the meaning of the Rules and Regulations, complied in
all material respects with the requirements of the Securities Act
and the Rules and Regulations and did not contain an untrue
statement of a material fact or omit to state a material fact
required to be stated therein or necessary to make the statements
therein, in the light of the circumstances under which they were
made, not misleading; except that the foregoing shall not apply to
statements in or omissions from any Preliminary Prospectus in
reliance upon, and in conformity with, written information relating
to any Underwriter furnished to the Company by you, or by any
Underwriter through you, specifically for use in the preparation
thereof.
(ii)
The Registration Statement and any Rule 462(b) Registration
Statement have been declared effective by the Commission under the
Securities Act. The Company has complied to the
Commission’s satisfaction with all requests of the Commission
for additional or supplemental information. No stop order
suspending the effectiveness of the Registration Statement or any
Rule 462(b) Registration Statement is in effect and no
proceedings for such purpose have been instituted or are pending
or, to the best knowledge of the Company, are contemplated or
threatened by the Commission.
(iii)
As of the time any part of the Registration Statement (or any
post-effective amendment thereto, including a registration
statement (if any) filed pursuant to Rule 462(b) of the Rules
and Regulations increasing the size of the offering registered
under the Securities Act) became effective, when any document filed
under the Exchange Act that is incorporated by reference into the
Registration Statement or the Prospectus was or is filed, upon the
filing or first use within the meaning of the Rules and Regulations
of the Prospectus (or any supplement to the Prospectus) and at the
First Closing Date and Second Closing Date (as hereinafter
defined), (A) the Registration Statement and the Prospectus
(in each case, as so amended and/or supplemented) conformed or will
conform in all material respects to the requirements of the
Securities Act and the Rules and Regulations, (B) the
Registration Statement (as so amended) did not or will not include
an untrue statement of a material fact or omit to state a material
fact required to be stated therein or necessary to make the
statements therein not misleading, and (C) the Prospectus (as
so supplemented) did not or will not include an untrue statement of
a material fact or omit to state a material fact required to be
stated therein or necessary to make the statements therein, in
light of the circumstances in which they are or were made, not
misleading; except that the foregoing shall not apply to statements
in or omissions from any such document in reliance upon, and in
conformity with, written information relating to any Underwriter
furnished to the Company by you, or by any Underwriter through you,
specifically for use in the preparation thereof. If the
Registration Statement has been declared effective by the
Commission, no stop order suspending the effectiveness of the
Registration Statement has been issued, and no proceeding for that
purpose has been initiated or, to the Company’s knowledge,
threatened by the Commission.
(iv)
As of the Applicable Time, neither (A) the Issuer-Represented
General Free Writing Prospectus(es) issued at or prior to the
Applicable Time, the Statutory Prospectus and the information
included on Schedule III hereto, all considered together
(collectively, the “ Pricing Disclosure Package
”), nor (B) any individual Issuer-Represented
Limited-Use Free Writing Prospectus, when considered together with
the Pricing Disclosure Package, included any untrue statement of a
material fact or omitted to state any material fact necessary in
order to make the statements therein, in the light of the
circumstances under which
3
they were made,
not misleading. The preceding sentence does not apply to
statements in or omissions from any Statutory Prospectus or any
Issuer-Represented Free Writing Prospectus based upon and in
conformity with written information furnished to the Company by you
or by any Underwriter through you specifically for use
therein. As used in this paragraph and elsewhere in this
Agreement:
(1)
“ Applicable Time ” means 5:00 pm (Eastern time)
on the date of this Agreement.
(2)
“ Statutory Prospectus ” as of any time means
the prospectus that is included in the Registration Statement
immediately prior to that time.
(3)
“ Issuer-Represented Free Writing Prospectus ”
means any “issuer free writing prospectus,” as defined
in Rule 433 under the Securities Act, relating to the Securities
that (A) is required to be filed with the Commission by the
Company, (B) is exempt from filing pursuant to Rule
433(d)(5)(i) under the Securities Act because it contains a
description of the Securities or of the offering that does not
reflect the final terms or is a “bona fide electronic road
show,” as defined in Rule 433 of the Rules and Regulations,
that is made available without restriction, in each case in the
form filed or required to be filed with the Commission or, if not
required to be filed, in the form retained in the Company’s
records pursuant to Rule 433(g) under the Securities
Act.
(4)
“ Issuer-Represented General Free Writing Prospectus
” means any Issuer-Represented Free Writing Prospectus that
is intended for general distribution to prospective investors, as
evidenced by its being specified in Schedule II to this
Agreement.
(5)
“ Issuer-Represented Limited-Use Free Writing
Prospectus ” means any Issuer-Represented Free Writing
Prospectus that is not an Issuer-Represented General Free Writing
Prospectus. The term Issuer-Represented Limited-Use Free
Writing Prospectus also includes any “bona fide electronic
road show,” as defined in Rule 433 of the Rules and
Regulations, that is made available without restriction pursuant to
Rule 433(d)(8)(ii), even though it is not required to be
filed with the Commission.
(v)
(A) Each
Issuer-Represented Free Writing Prospectus, as of its issue date
and at all subsequent times through the Prospectus Delivery Period
or until any earlier date that the Company notified or notifies the
Representatives as described in the next sentence, did not, does
not and will not include any information that conflicted, conflicts
or will conflict with the information contained in the Registration
Statement. If, at any time following issuance of an
Issuer-Represented Free Writing Prospectus, there occurred or
occurs an event or development as a result of which such
Issuer-Represented Free Writing Prospectus included or would
include an untrue statement of a material fact or omitted or would
omit to state a material fact necessary in order to make the
statements therein, in the light of the circumstances in which they
were made, not misleading, the Company has notified or will notify
promptly the Representatives so that any use of such
Issuer-Represented Free-Writing Prospectus may cease until it is
amended or supplemented. The foregoing two sentences do not
apply to statements in or omissions from any Issuer-Represented
Free Writing Prospectus based upon and in
4
conformity with
written information furnished to the Company by you or by any
Underwriter through you specifically for use therein.
(B)
(1) At the time of filing the Registration Statement, (2) at
the earliest time thereafter that the Company or another offering
participant made a bona fide offer (within the meaning of
Rule 164(h)(2) under the Securities Act) of the Securities and (3)
at the date hereof, the Company was not and is not an
“ineligible issuer,” as defined in Rule 405 under the
Securities Act (without taking account of any determination by the
Commission pursuant to Rule 405 that it is not necessary that the
Company be considered an ineligible issuer), nor an “excluded
issuer” as defined in Rule 164 under the Securities
Act.
(C)
Each Issuer-Represented Free Writing Prospectus, as of its issue
date and at all subsequent times through the Prospectus Delivery
Period, satisfied all other conditions to use thereof as set forth
in Rules 164 and 433 under the Securities Act.
(vi)
The financial statements of the Company, together with the related
notes, set forth or incorporated by reference in the Registration
Statement, the Pricing Disclosure Package and Prospectus comply in
all material respects with the requirements of the Securities Act
and the Exchange Act and fairly present the financial condition of
the Company as of the dates indicated and the results of operations
and changes in cash flows for the periods therein specified in
conformity with generally accepted accounting principles in the
United States consistently applied throughout the periods involved;
and the supporting schedules included in the Registration
Statement, the Pricing Disclosure Package or the Prospectus have
been derived from the accounting records of the Company and present
fairly the information required to be stated therein. No
other financial statements or schedules are required to be included
in the Registration Statement, the Pricing Disclosure Package or
Prospectus. To the Company’s knowledge,
PricewaterhouseCoopers LLP, which has expressed its opinion with
respect to the financial statements and schedules filed as a part
of the Registration Statement and included or incorporated by
reference in the Registration Statement, the Pricing Disclosure
Package and Prospectus, is (x) an independent public accounting
firm within the meaning of the Securities Act and the Rules and
Regulations, (y) a registered public accounting firm (as defined in
Section 2(a)(12) of the Sarbanes-Oxley Act of 2002 (the “
Sarbanes-Oxley Act ”)) and (z) in the performance of
its work for the Company, not in violation of the auditor
independence requirements of the Sarbanes-Oxley Act. Except
as described in the Pricing Disclosure Package and the Prospectus,
there are no material off-balance sheet transactions, arrangements,
obligations (including contingent obligations), or any other
relationships with unconsolidated entities or other persons, that
may have a material current or, to the Company’s knowledge,
future effect on the Company’s financial condition, changes
in financial condition, results of operations, liquidity, capital
expenditures, capital resources or significant components of
revenue or expenses.
(vii)
Each of the Company and its subsidiaries has been duly organized
and is validly existing as a corporation in good standing under the
laws of its jurisdiction of incorporation. Each of the Company and
its subsidiaries has full corporate power and authority to own its
properties and conduct its business as currently being carried on
and as described in the Registration Statement, the Pricing
Disclosure Package and Prospectus and is duly qualified to do
business as a foreign corporation in good standing in each
jurisdiction in which it owns or leases real property or in which
the conduct of its business makes such qualification
necessary
5
and in which the
failure to so qualify would result in a material adverse change in
the general affairs, business, prospects, properties, operations,
condition (financial or otherwise) or results of operations of the
Company and its subsidiaries, taken as a whole (“ Material
Adverse Change ”).
(viii)
Except as contemplated in the Pricing Disclosure Package and the
Prospectus, subsequent to the respective dates as of which
information is given in the Pricing Disclosure Package and the
Prospectus, neither the Company nor any of its subsidiaries has
incurred any material liabilities or obligations, direct or
contingent, or entered into any material transactions, or declared
or paid any dividends or made any distribution of any kind with
respect to its capital stock; and there has not been any change in
the capital stock (other than a change in the number of outstanding
shares of Common Stock due to the issuance of shares subject to
restricted stock awards under the Company’s 1997 Stock Option
and Incentive Plan (“1997 Incentive Plan”) or 2006
Long-Term Incentive Plan (“2006 Incentive Plan”), the
issuance of shares under the Company’s 1997 Employee Stock
Purchase Plan, or the issuance of shares upon the exercise of
outstanding options or warrants), or any material change in the
short term or long term debt, or any issuance of options, warrants,
convertible securities or other rights to purchase the capital
stock (except the grant of options and other rights to purchase
shares of the Company’s Common Stock under the
Company’s 1997 Incentive Plan, 1997 Director Stock Option
Plan or the 2006 Incentive Plan), of the Company or any of its
subsidiaries, or any Material Adverse Change or any development
involving a prospective Material Adverse Change.
(ix)
Except as set forth in the Pricing Disclosure Package and the
Prospectus, there is not pending or, to the knowledge of the
Company, threatened or contemplated, any action, suit or proceeding
to which the Company or any of its subsidiaries is a party or of
which any property or assets of the Company is the subject before
or by any court or governmental agency, authority or body, or any
arbitrator, which, individually or in the aggregate, might result
in any Material Adverse Change. There are no current or
pending legal, governmental or regulatory actions, suits or
proceedings that are required to be disclosed in the Registration
Statement, Pricing Disclosure Package or Prospectus that have not
been so described.
(x)
There are no statutes, regulations, contracts or documents that are
required to be described in the Registration Statement, the Pricing
Disclosure Package and the Prospectus or be filed as exhibits to
the Registration Statement by the Securities Act or by the Rules
and Regulations that have not been so described or
filed.
(xi)
This Agreement has been duly authorized, executed and delivered by
the Company, and constitutes a valid, legal and binding obligation
of the Company, enforceable in accordance with its terms, except as
rights to indemnity hereunder may be limited by federal or state
securities laws and except as such enforceability may be limited by
bankruptcy, insolvency, reorganization or similar laws affecting
the rights of creditors generally and subject to general principles
of equity. The execution, delivery and performance of this
Agreement and the consummation of the transactions herein
contemplated will not (A) conflict with or result in a breach or
violation of any of the terms or provisions of, or constitute a
default under, or result in the creation or imposition of any lien,
charge or encumbrance upon any property or assets of the Company
pursuant to, any indenture, mortgage, deed of trust, loan agreement
or other agreement or instrument to which the Company is a party or
by which the Company is bound or to which any of the property or
assets of the Company is subject, (B) result
6
in any violation
of the provisions of the charter or by-laws of the Company or (C)
result in the violation of any law or statute or any judgment,
order, rule or regulation of any court or arbitrator or
governmental or regulatory authority. No consent, approval,
authorization or order of, or filing with, any court or
governmental agency or body is required for the execution, delivery
and performance of this Agreement or for the consummation of the
transactions contemplated hereby, including the issuance or sale of
the Securities by the Company, except such as may be required under
the Securities Act or state securities or blue sky laws; and the
Company has full power and authority to enter into this Agreement
and to consummate the transactions contemplated hereby, including
the authorization, issuance and sale of the Securities as
contemplated by this Agreement.
(xii)
All of the issued and outstanding shares of capital stock of the
Company, including the outstanding shares of Common Stock, are duly
authorized and validly issued, fully paid and nonassessable, have
been issued in compliance with all federal and state securities
laws, were not issued in violation of or subject to any preemptive
rights or other rights to subscribe for or purchase securities that
have not been waived in writing (a copy of which has been delivered
to counsel to the Representatives), and the holders thereof are not
subject to personal liability by reason of being such holders; the
Securities which may be sold hereunder by the Company have been
duly authorized and, when issued, delivered and paid for in
accordance with the terms of this Agreement, will have been validly
issued and will be fully paid and nonassessable, and the holders
thereof will not be subject to personal liability by reason of
being such holders; and the capital stock of the Company, including
the Common Stock, conforms to the description thereof in the
Registration Statement, the Pricing Disclosure Package and the
Prospectus. Except as otherwise stated in the Registration
Statement, the Pricing Disclosure Package and the Prospectus, there
are no preemptive rights or other rights to subscribe for or to
purchase, or any restriction upon the voting or transfer of, any
shares of Common Stock pursuant to the Company’s charter, by
laws or any agreement or other instrument to which the Company is a
party or by which the Company is bound. Neither the filing of
the Registration Statement nor the offering or sale of the
Securities as contemplated by this Agreement gives rise to any
rights for or relating to the registration of any shares of Common
Stock or other securities of the Company. All of the issued
and outstanding shares of capital stock of each of the
Company’s subsidiaries have been duly and validly authorized
and issued and are fully paid and nonassessable, and, except as
otherwise described in the Registration Statement, the Pricing
Disclosure Package and the Prospectus and except for any
directors’ qualifying shares, the Company owns of record and
beneficially, free and clear of any security interests, claims,
liens, proxies, equities or other encumbrances, all of the issued
and outstanding shares of such stock. Neither the filing of
the Registration Statement nor the offering or sale of the
Securities as contemplated by this Agreement gives rise to any
rights for or relating to the registration of any shares of Common
Stock or other Securities of the Company that have not been fully
complied with or previously waived. Except as described in
the Registration Statement, the Pricing Disclosure Package and the
Prospectus, there are no options, warrants, agreements, contracts
or other rights in existence to purchase or acquire from the
Company or any subsidiary of the Company any shares of the capital
stock of the Company or any subsidiary of the Company. The
Company has an authorized and outstanding capitalization as set
forth in the Registration Statement, the Pricing Disclosure Package
and the Prospectus.
7
(xiii)
The Company and each of its subsidiaries holds, and is operating in
compliance in all material respects with, all franchises, grants,
authorizations, licenses, permits, easements, consents,
certificates and orders of any governmental or self regulatory body
required for the ownership or lease of its properties or the
conduct of its business, and all such franchises, grants,
authorizations, licenses, permits, easements, consents,
certifications and orders are valid and in full force and effect;
and neither the Company nor any of its subsidiaries has received
notice of any revocation or modification of any such franchise,
grant, authorization, license, permit, easement, consent,
certification or order or has reason to believe that any such
franchise, grant, authorization, license, permit, easement,
consent, certification or order will not be renewed in the ordinary
course; and the Company and each of its subsidiaries is in
compliance in all material respects with all applicable federal,
state, local and foreign laws, regulations, orders and
decrees.
(xiv)
The Company and its subsidiaries have good and marketable title to
all property (whether real or personal) described in the
Registration Statement, the Pricing Disclosure Package and the
Prospectus as being owned by them, in each case free and clear of
all liens, claims, security interests, other encumbrances or
defects except such as are described in the Registration Statement,
the Pricing Disclosure Package and the Prospectus. The
property held under lease by the Company and its subsidiaries is
held by them under valid, subsisting and enforceable leases with
only such exceptions with respect to any particular lease as do not
interfere in any material respect with the conduct of the business
of the Company or its subsidiaries.
(xv)
The Company and each of its subsidiaries owns, possesses, or can
acquire on reasonable terms, all Intellectual Property necessary
for the conduct of the Company’s and its susbsidiaries’
business as now conducted or as described in the Registration
Statement, the Pricing Disclosure Package and the Prospectus to be
conducted, except as such failure to own, possess, or acquire such
rights would not result in a Material Adverse Change.
Furthermore, (A) to the knowledge of the Company, there is no
infringement, misappropriation or violation by third parties of any
such Intellectual Property, except as such infringement,
misappropriation or violation would not result in a Material
Adverse Change; (B) there is no pending or, to the knowledge of the
Company, threatened, action, suit, proceeding or claim by others
challenging the Company’s or any of its subsidiaries’
rights in or to any such Intellectual Property, and the Company is
unaware of any facts which would form a reasonable basis for any
such claim; (C) the Intellectual Property owned by the Company and
its subsidiaries and, to the knowledge of the Company, the
Intellectual Property licensed to the Company and its subsidiaries,
has not been adjudged invalid or unenforceable, in whole or in
part, and there is no pending or threatened action, suit,
proceeding or claim by others challenging the validity or scope of
any such Intellectual Property, and the Company is unaware of any
facts which would form a reasonable basis for any such claim; (D)
there is no pending or threatened action, suit, proceeding or claim
by others that the Company or any of its subsidiaries infringes,
misappropriates or otherwise violates any Intellectual Property or
other proprietary rights of others, neither the Company or any of
its subsidiaries has received any written notice of such claim and
the Company is unaware of any other fact which would form a
reasonable basis for any such claim; and (E) to the Company’s
knowledge, no employee of the Company or any of its subsidiaries is
in or has ever been in violation of any term of any employment
contract, patent disclosure agreement, invention assignment
agreement, non-competition agreement, non-
8
solicitation
agreement, nondisclosure agreement or any restrictive covenant to
or with a former employer where the basis of such violation relates
to such employee’s employment with the Company nor any of its
subsidiaries or actions undertaken by the employee while employed
with the Company or any of its subsidiaries, except as such
violation would not result in a Material Adverse Change.
“Intellectual Property” shall mean all patents, patent
applications, trade and service marks, trade and service mark
registrations, trade names, copyrights, licenses, inventions, trade
secrets, technology, know-how and other intellectual
property.
(xvi)
Neither the Company nor any of its subsidiaries is (A) in violation
of its respective charter or by-laws; (B) in breach of or otherwise
in default, and no event has occurred which, with notice or lapse
of time or both, would constitute such a default in the performance
or observance of any term, covenant, obligation, agreement or
condition contained in any bond, debenture, note, indenture, loan
agreement, mortgage, deed of trust or any other contract, lease or
other instrument to which it is subject or by which it may be
bound, or to which any of the material property or assets of the
Company or any of its subsidiaries is subject; or (C) in violation
of any law or statute or any judgment, order, rule or regulation of
any court or arbitrator or governmental or regulatory
authority.
(xvii)
The Company and its subsidiaries have timely filed all federal,
state, local and foreign income and franchise tax returns required
to be filed and are not in default in the payment of any taxes
which were payable pursuant to said returns or any assessments with
respect thereto, other than any which the Company or any of its
subsidiaries is contesting in good faith. There is no pending
dispute with any taxing authority relating to any of such returns,
and the Company has no knowledge of any proposed liability for any
tax to be imposed upon the properties or assets of the Company for
which there is not an adequate reserve reflected in the
Company’s financial statements included in the Registration
Statement.
(xviii)
The Company has not distributed and will not distribute any
prospectus or other offering material in connection with the
offering and sale of the Securities other than any Preliminary
Prospectus, the Pricing Disclosure Package or the Prospectus or
other materials permitted by the Securities Act to be distributed
by the Company; provided, however, that, except as set forth on
Schedule III, the Company has not made and will not make any offer
relating to the Securities that would constitute a “free
writing prospectus” as defined in Rule 405 under the
Securities Act, except in accordance with the provisions of
Section 4(a)(xix) of this Agreement.
(xix)
The Common Stock is registered pursuant to Section 12(g) of
the Exchange Act and is included or approved for inclusion on The
NASDAQ Global Market, and the Company has taken no action designed
to, or likely to have the effect of, terminating the registration
of the Common Stock under the Exchange Act or delisting the Common
Stock from The NASDAQ Global Market nor has the Company received
any notification that the Commission or the National Association of
Securities Dealers, Inc. is contemplating terminating such
registration or listing. The Company has complied in all material
respects with the applicable requirements of The NASDAQ Global
Market for maintenance of inclusion of the Common Stock
thereon. The Company has filed an application to include the
Securities on The NASDAQ Global Market.
9
(xx)
Other than the subsidiaries of the Company listed in
Exhibit 21 to the Company’s Annual Report on Form 10-K
for the fiscal year ended December 31, 2005, Vital Images Holding
B.V., a corporation formed on May 19, 2006 under the laws of the
Netherlands and Vital Images Europe B.V., a corporation formed on
May 23, 2006 under the laws of the Netherlands, the Company,
directly or indirectly, owns no capital stock or other equity or
ownership or proprietary interest in any corporation, partnership,
association, trust or other entity.
(xxi)
The Company maintains a system of internal accounting controls
sufficient to provide reasonable assurances that
(A) transactions are executed in accordance with
management’s general or specific authorization;
(B) transactions are recorded as necessary to permit
preparation of financial statements in conformity with generally
accepted accounting principles and to maintain accountability for
assets; (C) access to assets is permitted only in accordance
with management’s general or specific authorization; and
(D) the recorded accountability for assets is compared with
existing assets at reasonable intervals and appropriate action is
taken with respect to any differences. Except as disclosed in
the Registration Statement, the Pricing Disclosure Package and the
Prospectus, the Company’s internal control over financial
reporting is effective and the Company is not aware of any material
weaknesses in its internal control over financial reporting, and
since the end of its latest audited fiscal year, there has been no
change in the Company’s internal control over financial
reporting (whether or not remediated) that has materially affected,
or is reasonably likely to materially affect, the Company’s
internal control over financial reporting.
(xxii)
Other than as contemplated by this Agreement, the Company has not
incurred any liability for any finder’s or broker’s fee
or agent’s commission in connection with the execution and
delivery of this Agreement or the consummation of the transactions
contemplated hereby.
(xxiii)
The Company is not and, after giving effect to the offering and
sale of the Securities, will not be an “investment
company,” as such term is defined in the Investment Company
Act of 1940, as amended.
(xxiv)
The conditions for use of Form S-3, set forth in the General
Instructions thereto, have been satisfied.
(xxv)
The documents incorporated by reference in the Registration
Statement, the Pricing Disclosure Package and the Prospectus, when
they became effective or were filed with the Commission, as the
case may be, conformed in all material respects to the requirements
of the Securities Act or the Exchange Act, as applicable, and were
filed on a timely basis with the Commission, and none of such
documents contained an untrue statement of a material fact or
omitted to state a material fact necessary to make the statements
therein, in the light of the circumstances under which they were
made, not misleading and, when such documents are read together
with the other information (A) in the Prospectus at the time the
Registration Statement became effective, (B) in the Pricing
Disclosure Package at the Applicable Time and (C) in the Prospectus
at the First Closing Date or Second Closing Date, did not and will
not contain an untrue statement of a material fact or omit to state
a material fact necessary to make the statements therein, in the
light of the circumstances under which they were made, not
misleading; any further documents so filed and incorporated by
reference in the Registration
10
Statement, the Pricing Disclosure
Package and the Prospectus, when such documents are filed with the
Commission, will conform in all material respects to the
requirements of the Exchange Act, and will not contain an untrue
statement of a material fact or omit to state a material fact
necessary to make the statements therein, in the light of the
circumstances under which they were made, not
misleading.
(xxvi)
The Company is in compliance with all applicable provisions of the
Sarbanes-Oxley Act and the rules and regulations of the Commission
thereunder.
(xxvii)
The Company has established and maintains disclosure controls and
procedures (as defined in Rules 13a-14 and 15d-14 under the
Exchange Act) and such controls and procedures are effective in
ensuring that material information relating to the Company,
including its subsidiaries, is made known to the Company’s
principal executive officer and principal financial officer.
The Company has utilized such controls and procedures in preparing
and evaluating the disclosures in the Registration Statement and
Prospectus.
(xxviii)
No relationship, direct or indirect, exists between or among the
Company, on the one hand, and the directors, officers,
stockholders, customers or suppliers of the Company, on the other
hand, which is required to be described in the Registration
Statement, the Pricing Disclosure Package and the Prospectus which
is not so described. The Company has not, directly or
indirectly, extended or maintained credit, or arranged for the
extension of credit, or renewed an extension of credit, in the form
of a personal loan to or for any of its directors or executive
officers in violation of applicable laws, including Section 402 of
the Sarbanes-Oxley Act.
(xxix)
Except as described in the Registration Statement, the Pricing
Disclosure Package and the Prospectus, the Company and each of its
subsidiaries: (A) is and at all times has been in full compliance
with all statutes, rules, regulations, or guidances applicable to
the ownership, testing, development, manufacture, packaging,
processing, use, distribution, marketing, labeling, promotion,
sale, offer for sale, storage, import, export or disposal of any
product manufactured or distributed by the Company or any of its
subsidiaries (“ Applicable Laws ”), except as
could not, individually or in the aggregate, reasonably be expected
to result in a Material Adverse Change; (B) has not received any
FDA Form 483, notice of adverse finding, warning letter, untitled
letter or other correspondence or notice from the U.S. Food and
Drug Administration or any other federal, state or foreign
governmental authority having authority over the Company (“
Governmental Authority ”) alleging or asserting
noncompliance with any Applicable Laws or any licenses,
certificates, approvals, clearances, authorizations, permits and
supplements or amendments thereto required by any such Applicable
Laws (“ Authorizations ”); (C) possesses all
material Authorizations and such Authorizations are valid and in
full force and effect and are not in violation of any term of any
such Authorizations; (D) has not received notice of any claim,
action, suit, proceeding, hearing, enforcement, investigation,
arbitration or other action from any Governmental Authority or
third party alleging that any product operation or activity is in
violation of any Applicable Laws or Authorizations and has no
knowledge that any such Governmental Authority or third party is
considering any such claim, litigation, arbitration, action, suit,
investigation or proceeding; (E) has not received notice that any
Governmental Authority has taken, is taking or intends to take
action to limit, suspend, modify or revoke any Authorizations and
has no knowledge that any such Governmental Authority is
considering such action; and (F) has filed, obtained, maintained or
submitted all material reports,
11
documents, forms,
notices, applications, records, claims, submissions and supplements
or amendments as required by any Applicable Laws or Authorizations
and that all such reports, documents, forms, notices, applications,
records, claims, submissions and supplements or amendments were
complete and correct in all material respects on the date filed (or
were corrected or supplemented by a subsequent
submission).
(xxx)
The Company and each of its subsidiaries (A) is in compliance
with any and all applicable federal, state, local and foreign laws,
rules, regulations, decisions and orders relating to the protection
of human health and safety, the environment or hazardous or toxic
substances or wastes, pollutants or contaminants (collectively,
“ Environmental Laws ”); (B) has received
and is in compliance with all permits, licenses or other approvals
required of it under applicable Environmental Laws to conduct its
business; and (C) has not received notice of any actual or
potential liability for the investigation or remediation of any
disposal or release of hazardous or toxic substances or wastes,
pollutants or contaminants, except in any such case for any such
failure to comply, or failure to receive required permits, licenses
or approvals, or liability as would not, individually or in the
aggregate, result in a Material Adverse Change.
(xxxi)
The Company and each of its subsidiaries (A) is in compliance,
in all material respects, with any and all applicable foreign,
federal, state and local laws, rules, regulations, treaties,
statutes and codes promulgated by any and all governmental
authorities (including pursuant to the Occupational Health and
Safety Act) relating to the protection of human health and safety
in the workplace (“ Occupational Laws ”);
(B) has received all material permits, licenses or other
approvals required of it under applicable Occupational Laws to
conduct its business as currently conducted; and (C) is in
compliance, in all material respects, with all terms and conditions
of such permit, license or approval. No action, proceeding,
revocation proceeding, writ, injunction or claim is pending or, to
the Company’s knowledge, threatened against the Company or
any of its subsidiaries relating to Occupational Laws, and the
Company does not have knowledge of any facts, circumstances or
developments relating to its operations or cost accounting
practices that could reasonably be expected to form the basis for
or give rise to such actions, suits, investigations or
proceedings.
(xxxii)
Each employee benefit plan, within the meaning of Section 3(3) of
the Employee Retirement Income Security Act of 1974, as amended
(“ ERISA ”), that is maintained, administered or
contributed to by the Company or any of its affiliates for
employees or former employees of the Company and its affiliates has
been maintained in compliance with its terms and the requirements
of any applicable statutes, orders, rules and regulations,
including but not limited to, ERISA and the Internal Revenue Code
of 1986, as amended (the “ Code ”). No
prohibited transaction, within the meaning of Section 406 of ERISA
or Section 4975 of the Code, has occurred with respect to any such
plan, excluding transactions effected pursuant to a statutory or
administrative exemption; and for each such plan that is subject to
the funding rules of Section 412 of the Code or Section 302 of
ERISA, no “accumulated funding deficiency,” as defined
in Section 412 of the Code, has been incurred, whether or not
waived, and the fair market value of the assets of each such plan
(excluding for these purposes accrued but unpaid contributions)
exceeds the present value of all benefits accrued under such plan
determined using reasonable actuarial assumptions.
(xxxiii)
Nothing has come to the attention of the Company that has caused
the Company to believe that the statistical and market-related data
included in the
12
Registration Statement, the Pricing
Disclosure Package and the Prospectus is not based on or derived
from sources that are reliable and accurate in all material
respects.
(xxxiv)
Neither the Company nor any of its affiliates is presently doing
business with the government of Cuba or with any person or
affiliate located in Cuba.
(xxxv)
The Company carries, or is covered by, insurance issued by insurers
of nationally recognized financial responsibility in such amounts
and covering such risks as is adequate for the conduct of its
business and the value of its properties and as is customary for
companies engaged in similar businesses in similar industries; and
the Company has (A) not received notice from any insurer or agent
of such insurer that capital improvements or other expenditures are
required or necessary to be made in order to continue such
insurance or (B) no reason to believe that it will not be able to
renew its existing insurance coverage as and when such coverage
expires or to obtain similar coverage at reasonable cost from
similar insurers as may be necessary to continue its
business. All such insurance is outstanding and duly in force
on the date hereof.
(xxxvi)
Neither the Company nor, to the best knowledge of the Company, any
director, officer, agent, employee or other person associated with
or acting on behalf of the Company has (A) used any corporate funds
for any unlawful contribution, gift, entertainment or other
unlawful expense relating to political activity; (B) made any
direct or indirect unlawful payment to any foreign or domestic
government official or employee from corporate funds; (C) violated
or is in violation of any provision of the Foreign Corrupt
Practices Act of 1977; or (D) made any bribe, rebate, payoff,
influence payment, kickback or other unlawful payment.
(xxxvii)
The Company acknowledges and agrees that: (A) the Representatives
have been retained solely to act as underwriters in connection with
the sale of the Securities and no fiduciary, advisory or agency
relationship between the Company and the Representatives has been
created in respect of any of the transactions contemplated by this
Agreement, irrespective of whether the Representatives have advised
or are advising the Company on other matters; (B) the price and
other terms of the Securities set forth in this Agreement were
established by the Company following discussions and
arm’s-length negotiations with the Representatives, and the
Company is capable of evaluating and understanding and understands
and accepts the terms, risks and conditions of the transactions
contemplated by this Agreement; (C) it has been advised that the
Representatives and their affiliates are engaged in a broad range
of transactions which may involve interests that differ from those
of the Company and the Representatives have no obligation to
disclose such interests and transactions to the Company by virtue
of any fiduciary, advisory or agency relationship; (D) it has been
advised that the Representatives are acting, in respect of the
transactions contemplated by this Agreement, solely for the benefit
of the Representatives and the other Underwriters, and not on
behalf of the Company; and (E) it waives, to the fullest extent
permitted by law, any claims it may have against the
Representatives for breach of fiduciary duty or alleged breach of
fiduciary duty in respect of any of the transactions contemplated
by this Agreement and agrees that the Representatives shall have no
liability (whether direct or indirect) to the Company in respect of
such a fiduciary duty claim on behalf of or in right of the
Company, including stockholders, employees or creditors of the
Company.
13
(b)
Any certificate signed by any officer of the Company and delivered
to you or to counsel for the Underwriters shall be deemed a
representation and warranty by the Company to each Underwriter as
to the matters covered thereby.
3.
Purchase, Sale and Delivery of Securities.
(a)
On the basis of the representations, warranties and agreements
herein contained, but subject to the terms and conditions herein
set forth, the Company agrees to issue and sell the Firm Shares to
the several Underwriters, and each Underwriter agrees, severally
and not jointly, to purchase from the Company the number of Firm
Shares set forth opposite the name of such Underwriter in Schedule
I hereto. The purchase price for each Firm Share shall be
$29.22 per share. The obligation of each Underwriter to the
Company shall be to purchase from the Company that number of Firm
Shares (to be adjusted by the Representatives to avoid fractional
shares) which represents the same proportion of the number of Firm
Shares to be sold by the Company pursuant to this Agreement as the
number of Firm Shares set forth opposite the name of such
Underwriter in Schedule I hereto represents to the total number of
Firm Shares to be purchased by all Underwriters pursuant to this
Agreement. In making this Agreement, each Underwriter is
contracting severally and not jointly; except as provided in
paragraph (c) of this Section 3 and in Section 8
hereof, the agreement of each Underwriter is to purchase only the
respective number of Firm Shares specified in Schedule
I.
The Firm Shares will be delivered by
the Company to you for the accounts of the several Underwriters
against payment of the purchase price therefor by wire transfer of
same day funds payable to the order of the Company at the offices
of Latham & Watkins LLP, 650 Town Center Drive, 20
th Floor, Costa Mesa, California 92626, or
such other location as may be mutually acceptable, at 9:00 a.m.
Central time on the third (or if the Securities are priced, as
contemplated by Rule 15c6-1(c) under the Exchange Act, after 4:30
p.m. Eastern time, the fourth) full business day following the date
hereof, or at such other time and date as you and the Company
determine pursuant to Rule 15c6-1(a) under the Exchange Act, such
time and date of delivery being herein referred to as the
“First Closing Date.” If the Representatives so
elect, delivery of the Firm Shares may be made by credit through
full fast transfer to the accounts at The Depository Trust Company
designated by the Representatives. Certificates representing
the Firm Shares, in definitive form and in such denominations and
registered in such names as you may request upon at least two
business days’ prior notice to the Company, will be made
available for checking and packaging not later than 10:30 a.m.,
Central time, on the business day next preceding the First Closing
Date at the offices of Piper Jaffray & Co., U.S. Bancorp
Center, 800 Nicollet Mall, Minneapolis, Minnesota, or such other
location as may be mutually acceptable.
(b)
On the basis of the representations, warranties and agreements
herein contained, but subject to the terms and conditions herein
set forth, the Company hereby grants to the several Underwriters an
option to purchase all or any portion of the Option Shares at the
same purchase price as the Firm Shares, for use solely in covering
any over allotments made by the Underwriters in the sale and
distribution of the Firm Shares. The option granted hereunder
may be exercised in whole or in part at any time (but not more than
once) within 30 days after the effective date of this
Agreement upon notice (confirmed in writing) by the Representatives
to the Company setting forth the aggregate number of Option Shares
as to which the several Underwriters are exercising the option, the
names and denominations in which the certificates for the Option
Shares are to be registered and the date and time, as determined by
you, when the
14
Option Shares are to be delivered,
such time and date being herein referred to as the “Second
Closing” and “Second Closing Date”, respectively;
provided, however, that the Second Closing Date shall not be
earlier than the First Closing Date nor earlier than the second
business day after the date on which the option shall have been
exercised. If the option is exercised, the number of Option
Shares to be purchased by each Underwriter shall be the same
percentage of the total number of Option Shares to be purchased by
the several Underwriters as the number of Firm Shares to be
purchased by such Underwriter is of the total number of Firm Shares
to be purchased by the several Underwriters, as adjusted by the
Representatives in such manner as the Representatives deem
advisable to avoid fractional shares. No Opt
|